Delving into Foundation Medicine's Recent ApprovalsDelving into Foundation Medicine's Recent Approvals

Dr. Geoffrey Oxnard vice president, global medical lead for Foundation Medicine's liquid biopsy portfolio, stops by Let's Talk Medtech to discuss the company’s recent FDA approvals. Oxnard also gives some insight into the liquid biopsy space.

Omar Ford

November 15, 2020

1 Min Read
IMG_Nov132020at40948PM.jpg
vectorfusionart-stock.adobe.com

Foundation Medicine has been busy with a number of approvals in recent weeks. The company, which was acquired by Roche in 2018 for $2.4 billion, recently won several approvals to be used as companion diagnostics. 

Dr. Geoffrey Oxnard vice president, global medical lead for  Foundation Medicine's liquid biopsy portfolio, stops by Let's Talk Medtech to discuss the company’s recent FDA approvals. Oxnard also gives some insight into the liquid biopsy space and the importance of tissue biopsies.

 

About the Author

Omar Ford

Omar Ford is a veteran reporter in the field of medical technology and healthcare journalism. As Editor-in-Chief of MD+DI (Medical Device and Diagnostics Industry), a leading publication in the industry, Ford has established himself as an authoritative voice and a trusted source of information.

Ford, who has a bachelor's degree in print journalism from the University of South Carolina, has dedicated his career to reporting on the latest advancements and trends in the medical device and diagnostic sector.

During his tenure at MD+DI, Ford has covered a wide range of topics, including emerging medical technologies, regulatory developments, market trends, and the rise of artificial intelligence. He has interviewed influential leaders and key opinion leaders in the field, providing readers with valuable perspectives and expert analysis.

 

Sign up for the QMED & MD+DI Daily newsletter.

You May Also Like